Neuren Pharmaceuticals Limited (NURPF)

Market Cap	1.03B +9.5%
Revenue (ttm)	43.12M -70.2%
Net Income	20.30M -78.6%
EPS	0.16 -78.6%
Shares Out	n/a
PE Ratio	50.61
Forward PE	98.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	1,305
Open	8.22
Previous Close	8.22
Day's Range	8.22 - 8.22
52-Week Range	6.60 - 14.80
Beta	1.61
RSI	37.27
Earnings Date	May 29, 2026

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: NURPF

Financial Performance

In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.

Financial numbers in AUD